araag2/HINT huggingface dataset:
Clinical trial NCT02643420 (phase 3, status: completed)
Conditions: neutropenia, breast cancer
ICD codes: D70.4, D70.8, D70.9, P61.5, D70.3, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: spi-2012, pegfilgrastim, docetaxel, cyclophosphamide
SMILES: CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Key Inclusion Criteria:

          -  New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as
             operable Stage I to Stage IIIA breast cancer.

          -  Candidate to receive adjuvant or neo-adjuvant TC chemotherapy.

          -  ECOG ≤2.

          -  ANC ≥1.5×10^9/L

          -  Platelet count ≥100×10^9/L

          -  Hemoglobin >9 g/dL

          -  Calculated creatinine clearance > 50 mL/min

          -  Total bilirubin ≤1.5 mg/dL

          -  AST/SGOT and ALT/SGPT ≤2.5×ULN

          -  Alkaline phosphatase ≤2.0×ULN

        Key Exclusion Criteria:

          -  Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of
             the cervix) or life-threatening disease.

          -  Known sensitivity to E. coli derived products or known sensitivity to any of the
             products to be administered during dosing

          -  Concurrent adjuvant cancer therapy

          -  Locally recurrent/metastatic

          -  Previous exposure to filgrastim, pegfilgrastim, or other G-CSF products in clinical
             development within 12 months prior to the administration of study drug

          -  Active infection or any serious underlying medical condition, which would impair the
             ability of the patient to receive protocol treatment

          -  Prior bone marrow or stem cell transplant

          -  Used any investigational drugs, biologics, or devices within 30 days prior to study
             treatment or plans to use any of these during the course of the study.

          -  Prior radiation therapy within 30 days prior to enrollment.

          -  Major surgery within 30 days prior to enrollment.
Clinical trial NCT02648204 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: semaglutide, dulaglutide
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O, CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria: - Male or female, age at least 18 years at the time of signing informed
        consent. - HbA1c (glycosylated haemoglobin) 7.0 - 10.5% (53 - 91 mmol/mol) (both inclusive)
        - Subjects on stable diabetes treatment with metformin (minimum of 1500 mg/day or maximal
        tolerated dose documented in the patient medical record) for 90 days prior to screening
        Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant
        or is of child-bearing potential and not using an adequate contraceptive method (adequate
        contraceptive measures as required by local regulation or practice) - Any condition, which
        in the investigator's opinion might jeopardise subject's safety or compliance with the
        protocol - Treatment with any medication for the indication of diabetes or obesity other
        than stated in the inclusion criteria in a period of 90 days before screening. An exception
        is short-term insulin treatment for acute illness for a total of equal to or below 14 days
        - History of pancreatitis (acute or chronic) - Screening calcitonin equal to or above 50
        ng/L - Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary
        Thyroid Carcinoma - Renal impairment defined as eGFR (electronic case report form) below 60
        mL/min/1.73 m^2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) -
        Subjects presently classified as being in New York Heart Association Class IV - Planned
        coronary, carotid or peripheral artery revascularisation on the day of screening -
        Proliferative retinopathy or maculopathy requiring acute treatment - History or presence of
        malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and
        in-situ carcinomas) - Anticipated initiation or change in concomitant medications (for more
        than 14 consecutive days or on a frequent basis) known to affect weight or glucose
        metabolism (e.g. orlistat, thyroid hormones, corticosteroids)
Clinical trial NCT02648217 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/insulin aspart, biphasic insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, age at least 18 years at the time of signing informed consent.
             Algeria: Male or female, age at least 19 years at the time of signing informed consent

          -  Subjects diagnosed (clinically) with type 2 diabetes mellitus prior to day of
             screening (Visit 1)

          -  Treated with any pre-mix/self-mix or basal insulin regimen for at least 90 days prior
             to the day of screening (Visit 1)

          -  Subjects not on any OAD(s) (oral anti-diabetic drug) prior to trial participation OR
             subjects on fixed daily dose(s) of OAD(s) for at least 90 days prior to screening
             (Visit 1). The OAD(s) include any of the following anti-diabetic drug(s)/regimen:
             Biguanides (metformin equal to or above 1500 mg or maximum tolerated dose documented
             in the subject medical record) Insulin secretagogues (sulfonylureas (SU) and
             glinides), Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), a-glucosidase
             inhibitors, Sodium-glucose co-transporter 2- inhibitors (SGLT2 Inhibitors ) (above or
             equal to half of the maximum approved dose according to local label or maximum
             tolerated dose as documented in subject medical record)

          -  HbA1c 7.0%-10.0% (53-86 mmol/mol) (both inclusive, by central laboratory analysis)

          -  Intention to fast (daytime, i.e., between dawn and sunset) during Ramadan after
             receiving medical counselling regarding the risk of fasting

          -  Willing to give blood during Ramadan

        Exclusion Criteria:

          -  Any contraindication for successful and sustained fasting from a medical perspective
             at the discretion of the investigator (such as acute illness, severe hypoglycaemia
             within 90 days prior to screening (Visit 1), hypoglycaemia unawareness, ketoacidosis
             within 90 days prior to screening (Visit), hyperosmolar hyperglycaemic coma within 90
             days prior to screening (Visit 1), subjects performing intense physical labour)
Clinical trial NCT02654054 (phase 3, status: completed)
Conditions: uterine fibroids, heavy menstrual bleeding
ICD codes: G43.831, G43.839, G43.821, G43.829, N94.9, N94.89
Drugs: elagolix, placebo for estradiol/norethindrone acetate, estradiol/norethindrone acetate, placebo for elagolix
SMILES: COC1=C(F)C(=CC=C1)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is a premenopausal female at the time of Screening.

          -  Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound
             (transabdominal ultrasound/transvaginal ultrasound).

          -  Subject has heavy menstrual bleeding associated with uterine fibroids as evidenced by
             menstrual blood loss > 80 mL during each of two screening menses as measured by the
             alkaline hematin method.

          -  Subject has negative urine and/or serum pregnancy test in Screening and just prior to
             first dose.

          -  Subject has an adequate endometrial biopsy performed during Screening, the results of
             which show no clinically significant endometrial pathology.

        Exclusion Criteria:

          -  Subject has screening pelvic ultrasound or saline infusion sonohysterography results
             that show a clinically significant gynecological disorder.

          -  Subject has history of osteoporosis or other metabolic bone disease.

          -  Subject has clinically significant abnormalities in clinical chemistry, hematology, or
             urinalysis.

          -  Subject has a history of major depression or post-traumatic stress disorder (PTSD)
             within 2 years of screening, OR a history of other major psychiatric disorder at any
             time (e.g., schizophrenia, bipolar disorder).

          -  Subject is using any systemic corticosteroids for over 14 days within 3 months prior
             to Screening or is likely to require treatment with systemic corticosteroids during
             the course of the study. Over the counter and prescription topical, inhaled,
             intranasal or injectable (for occasional use) corticosteroids are allowed.
Clinical trial NCT02654665 (phase 3, status: unknown status)
Conditions: non-alcoholic fatty liver disease (nafld), weight loss, non-alcoholic steatohepatitis (nash)
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0, R63.4
Drugs: liraglutide
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Body mass index > 27.5 kg/m2

          -  Waist circumference (WC) > 90 cm (male) or > 80 cm (female)

          -  Diagnosis of NASH based on Liver Function Test Results ,Ultrasound Hepato-Biliary
             System (HBS) findings and / or Liver Biopsy

          -  HbA1c < 8%* *Subjects in the bariatric surgery arm will not need to fulfil this
             criterion.

        Exclusion Criteria:

          -  Currently using insulin-sensitising agents (metformin, pioglitazone), weight loss
             medication (orlistat, phentermine). Patients taking any of these drugs will require a
             three month washout period before enrolment.

          -  Pregnancy

          -  Significant cardiovascular or respiratory disease

          -  Renal impairment with eGFR < 60 ml/min

          -  Hepatitis B or C carrier, liver disease other than NAFLD

          -  History of pancreatitis

          -  Personal or family history of multiple endocrine neoplasia type 2 or thyroid carcinoma

          -  Untreated hypothyroidism or hyperthyroidism

          -  Current psychiatric illness

          -  Cardiac pacemaker, metallic prosthetic heart valves and other contraindications to MRI
             scan

          -  Current smoker

          -  Alcohol intake ≥ 14 units/week
Clinical trial NCT02655016 (phase 3, status: active, not recruiting)
Conditions: ovarian neoplasms, ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: niraparib, placebo
SMILES: NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  Patient must have histologically confirmed, advanced (FIGO Stage III or IV) high-grade
             predominantly serous or endometrioid ovarian cancer, fallopian tube cancer, or primary
             peritoneal cancer who have completed first line platinum based chemotherapy
             (neoadjuvant or adjuvant)

          -  Patient must have clinical complete response or partial response following completion
             of chemotherapy course.

          -  All Stage IV patients are eligible, irrespective of residual disease, after primary or
             interval debulking. Stage III patients are required to have visible residual disease
             after primary surgery. Patients with inoperable Stage III and IV disease are eligible

          -  Patient must agree to undergo central tumor HRD testing

          -  Patients of childbearing potential must have negative pregnancy serum test within 72
             hours of being dosed

          -  Patient must be randomized within 12 weeks of the first day of the last cycle of
             chemotherapy

        Main Exclusion Criteria:

          -  Patient has mucinous or clear cell subtypes of epithelial ovarian cancer,
             carcinosarcoma or undifferentiated ovarian cancer

          -  Patient has undergone more than 2 debulking surgeries

          -  Patient is to receive bevacizumab as maintenance treatment

          -  Patient is pregnant, breastfeeding, or expecting to conceive children, while receiving
             study treatment and for 180 days after the last dose of study treatment

          -  Patient has had prior treatment with a known PARP inhibitor

          -  Patient has been diagnosed and/or treated for any invasive cancer (other than study
             disease) less than 5 years prior to study enrollment.
Clinical trial NCT02660138 (phase 3, status: terminated)
Conditions: urinary incontinence, overactive bladder
ICD codes: N39.492, R32, R39.81, N39.498, L24.A2, N32.81
Drugs: placebo, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    low recruitment of patients
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Urinary Incontinence for at least 3 months prior to Screening as a result of
             Neurogenic Detrusor Overactivity due to Spinal Cord Injury or Multiple Sclerosis.

          -  Subjects with Spinal Cord Injury must have a stable neurological injury at T1 level or
             below which occurred at least 6 months prior to Screening.

          -  Subjects with Multiple Sclerosis must be clinically stable in the investigator's
             opinion, with no exacerbation (relapse) of MS for at least 3 months prior to
             Screening.

          -  Subjects must have had an inadequate response after at least 4 weeks of oral
             medications used in the treatment of NDO (e.g. anticholinergics, beta-3 agonists)
             and/or have intolerable side-effects.

          -  Routinely performing Clean Intermittent Catheterization (CIC) to ensure adequate
             bladder emptying.

          -  An average of at least two episodes per day of Urinary Incontinence recorded on the
             screening bladder diary.

        Key Exclusion Criteria:

          -  Any current condition (other than NDO) that may impact on bladder function.

          -  Previous or current, tumour or malignancy affecting the spinal column or spinal cord,
             or any other unstable cause of SCI.

          -  Any condition that will prevent cystoscopic treatment administration or CIC usage,
             e.g. urethral strictures.

          -  Current indwelling bladder catheter, or removal of indwelling bladder catheter less
             than 4 weeks prior to Screening.

          -  BTX-A treatment within 9 months prior to Screening for any urological condition (e.g.
             detrusor or urethral sphincter treatments).

          -  Any neuromodulation/electrostimulation usage for urinary symptoms/incontinence within
             4 weeks prior to Screening. Any implanted neuromodulation device must be switched off
             at least 4 weeks prior to Screening.
Clinical trial NCT02660359 (phase 3, status: terminated)
Conditions: urinary incontinence, overactive bladder
ICD codes: N39.492, R32, R39.81, N39.498, L24.A2, N32.81
Drugs: placebo, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    low recruitment of patients
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Urinary Incontinence for at least 3 months prior to Screening as a result of
             Neurogenic Detrusor Overactivity due to Spinal Cord Injury or Multiple Sclerosis.

          -  Subjects with Spinal Cord Injury must have a stable neurological injury at T1 level or
             below which occurred at least 6 months prior to Screening.

          -  Subjects with Multiple Sclerosis must be clinically stable in the investigator's
             opinion, with no exacerbation (relapse) of MS for at least 3 months prior to
             Screening.

          -  Subjects must have had an inadequate response after at least 4 weeks of oral
             medications used in the treatment of NDO (e.g. anticholinergics, beta-3 agonists)
             and/or have intolerable side-effects.

          -  Routinely performing Clean Intermittent Catheterization (CIC) to ensure adequate
             bladder emptying.

          -  An average of at least two episodes per day of Urinary Incontinence recorded on the
             screening bladder diary.

        Key Exclusion Criteria:

          -  Any current condition (other than NDO) that may impact on bladder function.

          -  Previous or current, tumour or malignancy affecting the spinal column or spinal cord,
             or any other unstable cause of SCI.

          -  Any condition that will prevent cystoscopic treatment administration or CIC usage,
             e.g. urethral strictures.

          -  Current indwelling bladder catheter, or removal of indwelling bladder catheter less
             than 4 weeks prior to Screening.

          -  BTX-A treatment within 9 months prior to Screening for any urological condition (e.g.
             detrusor or urethral sphincter treatments).

          -  Any neuromodulation/electrostimulation usage for urinary symptoms/incontinence within
             4 weeks prior to Screening. Any implanted neuromodulation device must be switched off
             at least 4 weeks prior to Screening.
Clinical trial NCT02660905 (phase 3, status: unknown status)
Conditions: human immunodeficiency virus, hepatitis c, chronic
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4, B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: e/c/f/taf;, ledipasvir-sofosbuvir
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
Eligibility criteria:

        Inclusion

          -  HIV infected (ELISA with western blot confirmation)

          -  HCV RNA positive for minimum of 6 months / Genotype 1

          -  Prescribed cART that may include any DHHS recommended or alternative regimens, which
             the treating physician considers, is appropriate for their patient. (We anticipate
             that approximately 60% will be on HIV protease inhibitor-based regimens).

          -  HIV RNA BLLQ for minimum of 3 months

          -  Stage 0 - 4 fibrosis

          -  No evidence of liver decompensation defined as past or current ascites, bleeding
             varices or hepatic encephalopathy. Prior interferon, ribavirin and/or HCV protease
             inhibitor exposure will be allowed with the exception of cirrhotic with a past history
             of null response to interferon-based therapy.

          -  Ability to remain adherent to medications and study protocol as per investigator
             opinion

          -  For female subjects, not pregnant, planning or suspected to be pregnant or
             breast-feeding

          -  Willing to use acceptable methods of birth control, as defined in protocol

          -  Active substance use and/or mental health issues will not be exclusionary assuming
             other criteria are met. This inclusion will be restricted to those stably housed and
             engaged in harm reduction strategies. Our intent is to evaluate study participants who
             are representative of our clinical population and consider 'difficult to cure'
             compared to populations already evaluated in licensing studies

        Exclusion:

          -  Concomitant use of drugs with contraindication drug interactions with E/C/F/TAF of
             SOF-LDV

          -  History of HIV integrase inihbitors or NRTI resistance mutations

          -  Platelets <50 x109/L
Clinical trial NCT02662569 (phase 3, status: completed)
Conditions: diabetes, hyperlipidemia, mixed dyslipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: atorvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females with type 2 diabetes (receiving pharmacologic treatment for at least
             6 months or longer) with stable diabetes therapy

          -  Lipid-lowering therapy must be unchanged for at least 4 weeks or more

          -  Subjects receiving statin therapy at screening must have a fasting LDL-C of greater
             than or equal to 100 mg/dL

          -  Subjects not receiving statin therapy at screening must have a fasting LDL-C of
             greater than or equal to 130 mg/dL

        Exclusion criteria:

          -  New York Heart Association (NYHA) class III or IV heart failure

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension

          -  Type 1 diabetes or poorly controlled type 2 diabetes

          -  Uncontrolled hypothyroidism or hyperthyroidism.
Clinical trial NCT02665273 (phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: bupivacaine
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  ED patient with acute migraine or probable migraine

          -  Fail first line therapy with metoclopramide

        Exclusion Criteria:

          -  Can't obtain consent

          -  Concern for secondary headache

          -  Skull defect

          -  Propensity for bleeding

          -  Overlying infection

          -  Pregnancy

          -  Allergy, intolerance study medication
Clinical trial NCT02666664 (phase 3, status: completed)
Conditions: hypercholesterolemia, atherosclerotic cardiovascular diseases
ICD codes: E78.01, E78.00, Z83.42, Q93.81, B33.4, A36.81, A50.54, A52.00, A52.09, B33.24
Drugs: etc-1002, placebo
SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Fasting LDL-C ≥ 70 mg/dL

          -  High cardiovascular risk (diagnosis of HeFH or ASCVD)

          -  Be on maximally tolerated lipid-modifying therapy

        Exclusion Criteria:

          -  Total fasting triglyceride ≥500 mg/dL

          -  Renal dysfunction or nephrotic syndrome or history of nephritis

          -  Body Mass Index (BMI) ≥50kg/m2

          -  Significant cardiovascular disease or cardiovascular event in the past 3 months